Literature DB >> 28912033

Dissecting the CD93-Multimerin 2 interaction involved in cell adhesion and migration of the activated endothelium.

Federico Galvagni1, Federica Nardi2, Ottavia Spiga2, Alfonso Trezza2, Giulia Tarticchio3, Rosanna Pellicani3, Eva Andreuzzi3, Elena Caldi2, Paolo Toti4, Gian Marco Tosi5, Annalisa Santucci2, Renato V Iozzo6, Maurizio Mongiat7, Maurizio Orlandini8.   

Abstract

The glycoprotein CD93 has recently been recognized to play an important role in the regulation of the angiogenic process. Moreover, CD93 is highly expressed in the endothelial cells of tumor blood vessel and faintly expressed in the non-proliferating endothelium. Much evidence suggests that CD93 mediates adhesion in the endothelium. Here we identify Multimerin 2 (MMRN2), a pan-endothelial extracellular matrix protein, as a specific ligand for CD93. We found that CD93 and MMRN2 are co-expressed in the blood vessels of various human tumors. Moreover, disruption of the CD93-MMRN2 interaction reduced endothelial cell adhesion and migration, making the interaction of CD93 with MMRN2 an ideal target to block pathological angiogenesis. Model structures and docking studies served to envisage the region of CD93 and MMRN2 involved in the interaction. Site-directed mutagenesis identified different residue hotspots either directly or indirectly involved in the binding. We propose a molecular model in which the coiled-coil domain of MMRN2 is engaged by F238 of CD93. Altogether, these studies identify the key interaction surfaces of the CD93-MMRN2 complex and provide a framework for exploring how to inhibit angiogenesis by hindering the CD93-MMRN2 interaction.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angiogenesis; C1qRp; EDEN protein superfamily; Endothelial cell

Mesh:

Substances:

Year:  2017        PMID: 28912033     DOI: 10.1016/j.matbio.2017.08.003

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  17 in total

Review 1.  Extracellular matrix: The driving force of mammalian diseases.

Authors:  Renato V Iozzo; Maria A Gubbiotti
Journal:  Matrix Biol       Date:  2018-04-03       Impact factor: 11.583

Review 2.  C-type lectin family XIV members and angiogenesis.

Authors:  Supriya Borah; Dileep Vasudevan; Rajeeb K Swain
Journal:  Oncol Lett       Date:  2019-08-16       Impact factor: 2.967

3.  CD93 is Associated with Glioma-related Malignant Processes and Immunosuppressive Cell Infiltration as an Inspiring Biomarker of Survivance.

Authors:  Kaiming Ma; Suhua Chen; Xin Chen; Xiaofang Zhao; Jun Yang
Journal:  J Mol Neurosci       Date:  2022-08-25       Impact factor: 2.866

4.  The ablation of the matricellular protein EMILIN2 causes defective vascularization due to impaired EGFR-dependent IL-8 production affecting tumor growth.

Authors:  Alice Paulitti; Eva Andreuzzi; Dario Bizzotto; Rosanna Pellicani; Giulia Tarticchio; Stefano Marastoni; Chiara Pastrello; Igor Jurisica; Giovanni Ligresti; Francesco Bucciotti; Roberto Doliana; Roberta Colladel; Paola Braghetta; Evelina Poletto; Alessia Di Silvestre; Giorgio Bressan; Alfonso Colombatti; Paolo Bonaldo; Maurizio Mongiat
Journal:  Oncogene       Date:  2018-02-27       Impact factor: 9.867

5.  The small GTPase Rab5c is a key regulator of trafficking of the CD93/Multimerin-2/β1 integrin complex in endothelial cell adhesion and migration.

Authors:  Stefano Barbera; Federica Nardi; Ines Elia; Giulia Realini; Roberta Lugano; Annalisa Santucci; Gian Marco Tosi; Anna Dimberg; Federico Galvagni; Maurizio Orlandini
Journal:  Cell Commun Signal       Date:  2019-05-28       Impact factor: 5.712

6.  Common Molecular Alterations in Canine Oligodendroglioma and Human Malignant Gliomas and Potential Novel Therapeutic Targets.

Authors:  Dana Mitchell; Sreenivasulu Chintala; Kaleigh Fetcko; Mario Henriquez; Brij N Tewari; Atique Ahmed; R Timothy Bentley; Mahua Dey
Journal:  Front Oncol       Date:  2019-08-14       Impact factor: 6.244

Review 7.  Tumor angiogenesis: causes, consequences, challenges and opportunities.

Authors:  Roberta Lugano; Mohanraj Ramachandran; Anna Dimberg
Journal:  Cell Mol Life Sci       Date:  2019-11-06       Impact factor: 9.261

8.  Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy.

Authors:  Yi Sun; Wei Chen; Robert J Torphy; Sheng Yao; Gefeng Zhu; Ronggui Lin; Roberta Lugano; Emily N Miller; Yuki Fujiwara; Li Bian; Linghua Zheng; Sudarshan Anand; Fan Gao; Weizhou Zhang; Sarah E Ferrara; Andrew E Goodspeed; Anna Dimberg; Xiao-Jing Wang; Barish H Edil; Carlton C Barnett; Richard D Schulick; Lieping Chen; Yuwen Zhu
Journal:  Sci Transl Med       Date:  2021-07-28       Impact factor: 17.956

9.  CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis.

Authors:  Roberta Lugano; Kalyani Vemuri; Di Yu; Michael Bergqvist; Anja Smits; Magnus Essand; Staffan Johansson; Elisabetta Dejana; Anna Dimberg
Journal:  J Clin Invest       Date:  2018-06-25       Impact factor: 14.808

10.  The Binding of CD93 to Multimerin-2 Promotes Choroidal Neovascularization.

Authors:  Gian Marco Tosi; Giovanni Neri; Stefano Barbera; Lucia Mundo; Barbara Parolini; Stefano Lazzi; Roberta Lugano; Evelina Poletto; Lorenzo Leoncini; Grazia Pertile; Maurizio Mongiat; Anna Dimberg; Federico Galvagni; Maurizio Orlandini
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-07-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.